Humanized or chimeric CD3 antibodies
US11359015B2 · kind B2 · utility
4Cited by
12References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 14, 2016 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Nov 19, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.